Loading page…
The CA 125 (Cancer Antigen 125) test measures the level of CA 125 — a glycoprotein expressed on the surface of ovarian cancer c...
Also known as: CA-125 Blood Test · Cancer Antigen 125 · Ovarian Cancer Marker Test · CA125 Test
Limited Offer | Best Price Guaranteed
Loading price…
Loading price…
*Inclusive of home collection charges
The CA 125 (Cancer Antigen 125) test measures the level of CA 125 — a glycoprotein expressed on the surface of ovarian cancer cells and released into the bloodstream — in blood. CA 125 is the most important tumour marker for monitoring ovarian cancer treatment response and detecting recurrence after therapy. However, it is not sufficiently specific for population-level ovarian cancer screening — CA 125 can be elevated in many benign gynaecological conditions (endometriosis, fibroids, pelvic inflammatory disease) and non-gynaecological conditions. Its primary clinical value lies in monitoring, not initial diagnosis. No fasting required.
Key benefits of this package include:
What Does the CA 125 Test Measure?
| Level / Result | Possible Interpretation |
|---|---|
| < 35 U/mL (Normal) | CA 125 within reference range — ovarian cancer monitoring at baseline or in surveillance |
| 35–200 U/mL (Mildly-moderately elevated) | Non-specific elevation — possible endometriosis, fibroids, PID, pregnancy, liver disease, or early ovarian cancer; clinical and ultrasound correlation essential |
| > 200 U/mL (Significantly elevated) | Significantly elevated — high suspicion for ovarian cancer in post-menopausal women with pelvic mass; urgent gynaecological evaluation |
| Rising serial CA 125 during surveillance | Likely ovarian cancer recurrence — treatment planning review required even before clinical evidence |
| Falling CA 125 during chemotherapy | Positive treatment response — continued therapy appropriate; rate of fall correlates with prognosis |
| CA 125 normalised after chemotherapy | Clinical remission achieved — enter surveillance monitoring phase (CA 125 every 3–6 months) |
Important Note: CA 125 is NOT a reliable standalone screening test for ovarian cancer. Elevated CA 125 alone does not diagnose cancer — it must be interpreted alongside transvaginal ultrasound findings, menopausal status, and clinical symptoms. Many benign conditions cause elevated CA 125. Post-menopausal women with an ovarian mass and CA 125 above 35 U/mL have significantly elevated malignancy risk compared to pre-menopausal women. All results must be reviewed by a gynaecologist or oncologist.
CA 125 and Endometriosis — An Important Non-Cancer Association: CA 125 is significantly elevated in endometriosis — a condition where endometrial tissue grows outside the uterus, causing pelvic pain, dysmenorrhoea, and infertility. CA 125 levels in endometriosis typically range from 35–200 U/mL and broadly correlate with disease severity. While CA 125 cannot diagnose endometriosis (definitive diagnosis requires laparoscopy), serial CA 125 monitoring can track disease activity during medical treatment and help detect recurrence after surgery. This makes CA 125 clinically useful not just for cancer but as a monitoring tool in chronic endometriosis management.
Trusted by millions of Customers across South India — these are the tests our doctors recommend most.
Screens for anaemia, infections, and immune health
